The Leukemia & Lymphoma Society is the world’s largest voluntary health organization dedicated to funding blood cancer research and providing education and patient services.  Founded in 1949, we are relentless in pursuit of our mission: Cure leukemia, lymphoma, Hodgkin’s disease and myeloma, and improve the quality of life of patients and their families.
  
 Investing in blood cancer research: The Society has invested more than $424 million in research, $51.3 million in fiscal year 2005 alone.  Programs like the Specialized Center of Research (SCOR), which brings together teams of scientists from different disciplines and our Translational Research Program, which funds research with a high probability of producing innovative patient treatments in an accelerated time frame, have directly contributed to many breakthrough cancer treatments.
   
 Research funded by the Society has led or contributed to advances such as chemotherapy, bone marrow and stem cell transplantation and new, targeted oral therapies such as Gleevec®.
  
 Providing critical information and support for patients and their families:  We made 2.5 million contacts with patients, caregivers and healthcare professionals in fiscal year 2005, through our Information Resource Center (IRC), our award winning Web site and community-based patient service programs.  We put people together with experts through Web- casts and teleconferences, and provided professional education through seminars, to extend the latest findings to a broader professional audience.
  
 Advocating for issues impacting blood cancer patients: With more than 20,000 advocacy volunteers throughout the country, our voice is being heard by those responsible for legislation to fund blood cancer research and educational programs.
  
 The need is critical: More than 747,000 Americans have leukemia, Hodgkin or non-Hodgkin lymphoma or myeloma.  Every five minutes, someone new is diagnosed with blood cancer.  Every 10 minutes, someone dies.
  
 Leukemia causes more deaths than any other cancer among children under the age of 20.  Lymphomas are the most common blood cancers and incidence increases with age.  The survival rate for myeloma is only 32.4 percent.  Incidence is more than twice as high among African Americans as for all other races.
  
 As a nonprofit, we rely on the generosity of individuals, corporations and foundations.  Seventy-five percent of our total expenses support cancer research, education, advocacy and patient services.  Major, annual fundraising campaigns include Team In Training®, Light The Night® Walk, School & Youth ProgramsSM, Man & Woman of the Year. The Leukemia Cup Regatta and now Shoot For A Cure.
 
 In addition to our national headquarters in White Plains, NY, we have a network of 66 local chapters across the United States and Canada.  Information on blood cancers and support is available through the IRC and at www.LLS.org.